CU23787B7 - MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION - Google Patents

MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION

Info

Publication number
CU23787B7
CU23787B7 CU20090209A CU20090209A CU23787B7 CU 23787 B7 CU23787 B7 CU 23787B7 CU 20090209 A CU20090209 A CU 20090209A CU 20090209 A CU20090209 A CU 20090209A CU 23787 B7 CU23787 B7 CU 23787B7
Authority
CU
Cuba
Prior art keywords
inhibitors
viral replication
macrocyclic compounds
formula
hcv
Prior art date
Application number
CU20090209A
Other languages
Spanish (es)
Other versions
CU20090209A7 (en
Inventor
Benjamin Woodard
George Andrew Doherty
Machender R Madduru
Peter John Stengel
John Anthony Josey
Kevin Ronald Condroski
April Layne Kennedy
Yutong Jiang
Steven Wade Andrews
Steven Mark Wenglowsky
Lawrence M Blatt
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of CU20090209A7 publication Critical patent/CU20090209A7/en
Publication of CU23787B7 publication Critical patent/CU23787B7/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con el compuesto de la fórmula ESPACIO PARA LA FÓRMULA procesos para su síntesis, composiciones farmacéuticas y métodos para el tratamiento de infecciones flavivirales, tales como infección por el virus de la hepatitis C (HCV).The present invention relates to the compound of the formula SPACE FOR FORMULA processes for its synthesis, pharmaceutical compositions and methods for the treatment of flaviviral infections, such as hepatitis C virus (HCV) infection.

CU20090209A 2004-03-30 2009-12-08 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION CU23787B7 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55816104P 2004-03-30 2004-03-30
US56241804P 2004-04-14 2004-04-14
US61246004P 2004-09-22 2004-09-22
US61238104P 2004-09-22 2004-09-22

Publications (2)

Publication Number Publication Date
CU20090209A7 CU20090209A7 (en) 2011-04-26
CU23787B7 true CU23787B7 (en) 2012-03-15

Family

ID=35005653

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090209A CU23787B7 (en) 2004-03-30 2009-12-08 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION

Country Status (16)

Country Link
EP (1) EP1749007A2 (en)
JP (1) JP4950026B2 (en)
AP (1) AP2006003763A0 (en)
AR (1) AR050321A1 (en)
AU (1) AU2005228894B9 (en)
BR (1) BRPI0509467A (en)
CA (1) CA2560897C (en)
CU (1) CU23787B7 (en)
EA (1) EA012389B1 (en)
EC (1) ECSP066959A (en)
GE (1) GEP20104926B (en)
IL (1) IL177917A0 (en)
MA (1) MA28548B1 (en)
NO (1) NO20064933L (en)
NZ (1) NZ549697A (en)
WO (1) WO2005095403A2 (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101160317B (en) * 2005-03-08 2013-03-27 贝林格尔·英格海姆国际有限公司 Process for preparing macrocyclic compounds
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI387603B (en) 2005-07-20 2013-03-01 Merck Sharp & Dohme Hcv ns3 protease inhibitors
EP2305697A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
MY144607A (en) * 2005-07-29 2011-10-14 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA96283C2 (en) 2005-12-23 2011-10-25 Зіланд Фарма А/С Modified lysine-mimetic compounds
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7906619B2 (en) 2006-07-13 2011-03-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101568543B (en) * 2006-11-16 2012-06-06 百时美施贵宝公司 Macrocyclic peptides as hepatitis c virus inhibitors
US7763584B2 (en) * 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20080188545A1 (en) 2006-12-21 2008-08-07 Alimardanov Asaf R Synthesis of pyrrolidine compounds
US20100323953A1 (en) * 2007-01-08 2010-12-23 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
WO2008096002A1 (en) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates
EP2495249A1 (en) 2007-02-26 2012-09-05 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AP2009005053A0 (en) 2007-05-03 2009-12-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
WO2009005677A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
AR067442A1 (en) * 2007-06-29 2009-10-14 Gilead Sciences Inc ANTIVIRAL COMPOUNDS
WO2009005690A2 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
SE531698C2 (en) 2007-07-12 2009-07-07 Respiratorius Ab New bronchodilating a, b unsaturated amides
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
AU2008340257B2 (en) 2007-12-21 2015-06-11 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
NZ586232A (en) 2007-12-21 2012-12-21 Avila Therapeutics Inc HCV protease inhibitors comprising a functionalised proline derivative
CN101910177B (en) * 2007-12-24 2013-08-28 泰博特克药品公司 Macrocyclic indoles as hepatitis C virus inhibitors
WO2009124853A1 (en) * 2008-04-11 2009-10-15 F. Hoffmann-La Roche Ag New ruthenium complexes as catalysts for metathesis reactions
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009148923A1 (en) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
ES2461841T3 (en) * 2008-08-07 2014-05-21 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
AU2009293493B2 (en) 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009324643B2 (en) 2008-12-10 2014-08-28 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR074897A1 (en) 2008-12-23 2011-02-23 Pharmasset Inc NUCLEOSID PHOSPHORAMIDATES
SG172361A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside analogs
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
CN104478868A (en) 2009-02-27 2015-04-01 奥索-麦克尼尔-詹森药品公司 Amorphous salt of a macrocyclic inhibitor of HCV
CA2758072A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
WO2010132442A1 (en) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
EP2429293B1 (en) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
GEP20146016B (en) 2009-07-07 2014-01-27 Boehringer Ingelheim Int Pharmaceutical composition containing hepatitis c viral protease inhibitor
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
KR20120110090A (en) * 2009-09-28 2012-10-09 에프. 호프만-라 로슈 리미티드 Novel macrocyclic inhibitors of hepatitis c virus replication
WO2011053617A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
EP2528436A4 (en) 2010-01-25 2013-07-10 Enanta Pharm Inc Hepatitis c virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
PT3290428T (en) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
UY33312A (en) 2010-03-31 2011-10-31 Pharmasset Inc PURINE NUCLEOSIDE PHOSPHORAMIDATE
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
CN103313968A (en) 2010-11-15 2013-09-18 Abbvie公司 Nampt and rock inhibitors
PT3042910T (en) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-spiro-nucleosides for use in the therapy of hepatitis c
EA201390988A1 (en) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. PHENANTRIDINE MACROCYCLIC INHIBITORS OF THE HYPATITIS C VIRUS SERIN PROTEASE
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
AR085352A1 (en) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc MACROCICLIC INHIBITORS OF SERINA PROTEASA, ITS PHARMACEUTICAL COMPOSITIONS AND ITS USE TO TREAT HCV INFECTIONS
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AU2012382373A1 (en) 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
EA025560B1 (en) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9115175B2 (en) 2013-03-14 2015-08-25 Achillion Pharmaceuticals, Inc. Processes for Producing sovaprevir
BR112015023351A2 (en) 2013-03-15 2017-07-18 Achillion Pharmaceuticals Inc crystalline form of sovaprevir, pharmaceutical composition, and method for treating a disorder
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
AU2014311827B2 (en) 2013-08-27 2017-09-14 Gilead Sciences, Inc. Combination formulation of two antiviral compounds
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN110709096B (en) 2017-05-05 2023-10-31 泽兰德制药公司 Cell gap junction communication regulator and application thereof in treatment of diabetic eye disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (en) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd INHIBITING PEPTIDES OF HEPATITIS C, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, THE USE OF THE SAME TO PREPARE A PHARMACEUTICAL COMPOSITION, THE USE OF AN INTERMEDIATE PRODUCT FOR THE PREPARATION OF THESE PEPTIDES AND A PROCEDURE FOR THE PREPARATION OF ANOGRAPH .
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
AU2002248147B2 (en) * 2000-11-20 2006-04-06 Bristol-Myers Squibb Company Hepatitis C tripeptide inhibitors
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2370396A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
PL211889B1 (en) * 2002-05-20 2012-07-31 Bristol Myers Squibb Co Heterocyclicsulfonamide hepatitis c virus inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
TW201245229A (en) * 2003-10-14 2012-11-16 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
CA2552317C (en) * 2004-01-30 2013-12-10 Medivir Ab Hcv ns-3 serine protease inhibitors

Also Published As

Publication number Publication date
NZ549697A (en) 2009-12-24
CU20090209A7 (en) 2011-04-26
WO2005095403A3 (en) 2005-12-01
NO20064933L (en) 2006-12-15
EP1749007A2 (en) 2007-02-07
EA012389B1 (en) 2009-10-30
IL177917A0 (en) 2006-12-31
JP2007531749A (en) 2007-11-08
MA28548B1 (en) 2007-04-03
BRPI0509467A (en) 2007-09-11
AP2006003763A0 (en) 2006-10-31
CA2560897C (en) 2012-06-12
EA200601467A1 (en) 2007-06-29
WO2005095403A2 (en) 2005-10-13
GEP20104926B (en) 2010-03-25
AU2005228894B2 (en) 2011-08-25
ECSP066959A (en) 2006-12-20
AU2005228894A1 (en) 2005-10-13
CA2560897A1 (en) 2005-10-13
AR050321A1 (en) 2006-10-18
AU2005228894B9 (en) 2011-10-13
JP4950026B2 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
CU23787B7 (en) MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
EA200800371A1 (en) HCV Protease Inhibitors
EA200901101A1 (en) MACROCYCLIC COMPOUNDS AS INHIBITORS OF HCV PROTEASIS NS3
MX2009004556A (en) Hcv ns3 protease inhibitors.
EA201000201A1 (en) NITROGEN-CONTAINING BICYCLIC CHEMICALS FOR THE TREATMENT OF VIRAL INFECTIONS
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
CO6440581A2 (en) HEPATITIS C VIRUS INHIBITORS
WO2013074386A3 (en) Hcv ns3 protease inhibitors
MX2011006631A (en) Hcv ns3 protease inhibitors.
WO2006119061A3 (en) Hcv ns3 protease inhibitors
CO6290682A2 (en) INHIBITING FUSIONED TRICICLIC COMPOUNDS OF HEPATITIS VIRUS C.
BR112012011100A2 (en) hepatitis virus inhibitor compounds, composition and use thereof
WO2008051477A3 (en) Hcv ns3 protease inhibitors
TW200720285A (en) Nucleoside compounds for treating viral infections
CL2004001161A1 (en) COMPOUNDS DESCRIBES COMPOUNDS DERIVED FROM QUINOLINA; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT AN ILLNESS CAUSED BY THE HEPATITIS C VIRUS.
CO6561788A2 (en) HEPATITIS C VIRUS INHIBITORS
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
EA200800178A1 (en) HEPATITIS C VIRUS INHIBITORS (HCV)
EA200701849A1 (en) TRUNCTIONAL COMPOUNDS OF TRICYCLIC NUCLEOSIDES, PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND METHOD OF TREATMENT AND / OR INHIBITION OF VIRAL INFECTION IN THE MAMMALIAN
EA201171174A1 (en) HEPATITIS C VIRUS REPLICATION INHIBITORS
ATE526341T1 (en) MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS
CO6400192A2 (en) HEPATITIS C VIRUS INHIBITORS
NO20090453L (en) Hepatitis C Virus Inhibitors

Legal Events

Date Code Title Description
FG Grant of patent